Study wrapper · #509
Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model.
Editor's note
This is a preclinical rat study (120 Sprague-Dawley rats) examining how antiretroviral regimens and calorie-dense diets affect the heart's electrical activity and tissue structure, with tesamorelin included as one treatment arm. Researchers reported that dolutegravir-based and classical antiretroviral regimens combined with calorie-dense diets were associated with marked electrocardiographic changes and myocardial fibrosis, and that adding tesamorelin was associated with an absence of these effects. Tesamorelin is a supporting element here rather than the primary focus, and the design is a rodent model — a mechanistic signal implicating the growth-hormone pathway, not clinical proof. These are preclinical findings; human data are needed before clinical conclusions can be drawn. The result is broadly consistent with tesamorelin's known metabolic effects but should be weighted accordingly.
Plain-language abstract
Researchers fed 120 young rats one of three diets (normal, or two calorie-dense diets) for 15 weeks, then added HIV drug regimens for another 9 weeks. Some groups also received tesamorelin, a lab-made growth-hormone-releasing hormone. At the end, heart tracings (ECGs) and heart-tissue samples showed that the calorie-dense diets combined with the HIV drug regimens were associated with abnormal electrical patterns and scarring (fibrosis) of the heart muscle, which can disturb the heart's rhythm. Animals that also received tesamorelin did not show these heart changes. The authors suggest the growth-hormone pathway is involved in the damage. This was an animal study; the findings describe rat biology and cannot be applied directly to people. No serious adverse effects were described in the report.